Quote this publication Share Print

OXYCONTIN - OXYNORM - OXYNORMORO

-
Opinions on drugs - Posted on Apr 02 2013

Reason for request

Renewal of inclusion on the list of medicines refundable by National Health Insurance and extension of the indication for non-cancer related pain for all forms OXYCONTIN PR, OXYNORM and OXYNORMORO including those included for hospital use only.

-


Actual benefit

Insuffisant

the actual benefit of these proprietary medicinal products in comparison with the treatments that are already available for this type of pain is not sufficient to justify reimbursement by National Health Insurance

Important

The actual benefit of these proprietary medicinal products remains substantial in the treatment of cancer-related pain, which can be adequately managed only by opioid analgesics.

The actual benefit of these proprietary medicinal products is substantial in the treatment of non-cancer-related pain.

The actual benefit of these proprietary medicinal products is substantial in the treatment of neuropathic pain.




Improvement in actual benefit

V (absence)

OXYCONTIN, OXYNORM and OXYNORMORO do not provide an improvement in actual benefit (IAB V) in comparison with immediate- and prolonged-release morphine-based products in the management of severe cancer-related, post-operative and neuropathic pain.


Contact Us

Évaluation des médicaments

See also